Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

UNCOVERED: 26 | History Defined

Chart of the Day: Eli Lilly (LLY) Edges to New Record High

The Barchart Chart of the Day belongs to Eli Lilly (LLY) . I found the stock by using Barchart.com to find the "Barchart New Highs" page, and then I clicked on pull-down to select stocks with new 52-week highs. I then viewed the stocks on the list with the FlipCharts...

Barchart

A trial to test a new path for preventing Alzheimer’s

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

The Hindu

Insulin Patients Can Find Discounts With Amazon's New Automated Coupon System

Amazon Pharmacy will automatically apply manufacturer-sponsored coupons for 15-plus products.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Tesla Hires New Exec To Lead Giga Nevada's Massive $3.6B Expansion

Before joining Tesla in July, Michael Hildebrand was executive director of projects at Eli Lilly, where he spent the previous 19 years of his career.

InsideEVs

Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Kiplinger

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

The Independent UK

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

WEKU

Read news from The Economist, FT, and more,
with one subscription

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

The Conversation

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

The Conversation

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

StockNews.com

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

The Independent UK

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

Evening Standard

What impact will Alzheimer’s drug donanemab have?

While it is not a cure, proof that drugs can alter course of disease is regarded as significant triumph

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

Fortune

Ozempic isn't alone. A whole class of 'revolutionary' weight-loss drugs is on the market—but only for the wealthy

“We're experiencing something here that is very, very different, very exciting from a healthcare perspective, and very expensive,” says Aon's Michael Manolakis.

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

The Guardian - UK

Revealed: pharma giants pour millions of pounds into NHS to boost drug sales

Observer investigation raises concerns about the influence of drugs companies in shaping patient care in services that use their products

Get all your
news in one place.

100's of premium titles.
One news app.

Zenger

FDA Approves Biogen’s Alzheimer’s Drug That Slows Down Cognitive Decline

The FDA fully approved Biogen Inc. but there are other companies with treatments in the pipeline

StockNews.com

3 Stocks to Own as Alzheimer's Drugs Bring Relief

The number of people with dementia, including those with Alzheimer's disease, are projected to increase from 50+ million now to more than 150 million in 2050, according to Alzheimer's Disease International. Those sheer numbers will mean that investors in certain stocks, producing Alzheimer's drugs to combat the disease, are poised…

Nottingham Post

Weight loss jab rejected for NHS use over effectiveness concerns - despite positive trials

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

Wales Online

Weight loss injection rejected for NHS use over effectiveness concerns

More evidence is needed if the treatment is to be approved for NHS use, England drugs watchdog says

The Guardian - UK

Weight-loss jab rejected for NHS use by England drugs watchdog

Nice says more evidence needed on effectiveness of tirzepatide, sold under brand name Mounjaro

The Independent UK

More info needed on weight-loss jab’s impact on type 2 diabetes – Nice

The once-weekly jab would be offered to diabetic patients alongside diet and exercise,

Fortune

Eli Lilly’s CEO pinpoints the 3-pronged problem big execs face with remote work

Managing a distributed workforce is “the leadership challenge of our decade,” David Ricks, CEO of pharma giant Eli Lilly, said.

1 … 25 26 27 28

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Centers for Disease Control and Prevention

244 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.